

Dennis M. Erb, Ph.D.  
Senior Director  
Regulatory Affairs

Merck & Co., Inc.  
P.O. Box 4, BLA-20  
West Point PA 19486  
Tel 610 397 7597  
215 652 5000  
Fax 610 397 2516

2092 '99 OCT 27 19:25

October 26, 1999

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane Rm. 1061  
Rockville, MD 20852



**Docket No. 99D-2635**  
**Draft Guidance for Industry on ANDA's:**  
**Blend Uniformity Analysis**

Merck & Co., Inc. is a leading worldwide, human health product company. Merck's corporate strategy -- to discover new medicines through breakthrough research -- encourages us to spend more than \$2 Billion, annually, on worldwide Research and Development (R & D). Through a combination of the best science and state-of-the-art medicine, Merck's R & D pipeline has produced many of the important pharmaceutical products on the market, today.

Merck supports regulatory oversight of product development that is based on sound scientific principles and good medical judgment. Regulators must be reasonable, unbiased and efficient when they review the quality, effectiveness and safety of our products. It is in both of our interests to see that important therapeutic advances reach patients without unnecessary or unusual delays.

As an innovative research and development company, Merck constantly explores new opportunities to improve the transfer of technology from the research laboratories to our manufacturing facilities. With a vision that validation is a continuum, Merck establishes a system of in-process controls and testing procedures during product development to ensure the quality of our marketed products. Thus Merck is affected by regulations which impact the in-process and finished product testing requirements to ensure product quality. For these reasons, we are very interested in and well qualified to comment on this Draft FDA guidance on ANDA's: Blend Uniformity Analysis.

**General Comments**

The proposed guidance reflects an issue discussed by FDA personnel during public presentations over the past few years. FDA refers to section of 21 CFR 211.110(a)(3) as the regulatory driver requiring blend uniformity analysis (BUA) during the manufacture of drug products. In summary, this section of the CFR states that manufacturers shall establish appropriate controls to monitor process performance and demonstrate adequate mixing to assure batch uniformity and homogeneity. The guidance document describes BUA as a "useful" test regime for assuring adequate mixing and recommends BUA be included as an in-process cGMP test requirement.

99D-2635

C17

We agree that uniformity of blends should be demonstrated as required by 21 CFR 211.110(a)(3). However, this requirement can be accomplished during validation of the blending process. The requirement for BUA as a routine in-process test regime conflicts in principle with the concept of process and blend validation. Implementation of BUA for a validated blending process in effect provides validation-type information with each batch. While this additional information may provide additional “comfort” that a blend is homogeneous, validation of the process/blend mix parameters is intended to provide the assurance of blend uniformity and routine analysis of each batch is unnecessary.

Problems associated with obtaining a representative sample of bulk powders are well known. PDA Technical Report 25 explores the issues associated with BUA, both during validation and as an in-process control parameter. Much of the report is dedicated to the difficulties associated with current limitations in sampling technologies. The report states “numerous publications cite the existence of sampling error in sampling large powder beds with thieves and the non statistically based criteria imposed on such samples . . . blend sampling at micro levels using existing sampling technologies often yields samples that are not representative of the product.” Although obtaining representative samples of a blend has been demonstrated to be problematic, it is nevertheless difficult to invalidate a test failure and conclude that a sampling error occurred. This would result in the rejection of material that would result in, if processed to drug product, material that fully meets its quality and purity acceptance criterion.

While the concept of BUA could result in improved knowledge and control of a process, it would seem that the same information, namely blend homogeneity, could be gathered based on extended testing of the drug product. Performing extensive testing (10 intervals) for Content Uniformity across a batch of final product may provide the assurance intended to be provided by BUA. While neither approach should be necessary for a well controlled and validated process and the concept seems duplicitous with the concept of process validation, extensive product sampling and testing could be accomplished without the inherent risks associated with blend sampling.

The guidance document states that FDA intends to seek the support of the Product Quality Research Institute (PQRI) on the issue of BUA. PQRI is a collaborative process involving FDA's Center for Drug Evaluation and Research (CDER), Industry and Academia. The stated mission of PQRI is to conduct research to generate scientific information to support regulatory policy. It seems premature to issue a draft guidance document on BUA, where technical merit and sampling error are in question, before obtaining supporting data through PQRI.

### **Specific Comments**

Page 2 – the document states that BUA “is not usually necessary” for drug product where the active is  $\geq 50\%$  of the drug product or where the active composition is  $\geq 50$  mg. The statement “not usually necessary” is very nondescript and could likely lead to differences in interpretation between FDA investigators.


Page 4 – Acceptance criteria for BUA is stated as 90 to 110% of label claim. This is much tighter than then final dosage Content Uniformity requirements of 85 to 115% listed in the USP. There is no justification for setting BUA acceptance criteria at this level.

Page 7 – the document defines “In-process Controls” as “tests that can be performed during the manufacture” of a drug. This very narrowly defines the term “controls” in the regard of testing, in this specific case as blend uniformity testing. However, a broader perspective must be applied to the term “in-process controls” to include in-process control parameters. This broader perspective more directly supports the fundamentals of process validation where appropriate “in-process parameters” are used to assure process control and consistency. “Blend testing” would only provide confirmation that the critical process parameters (such as blend time, revolutions, *etc.*) provided the “validated” level of control.

In conclusion, without careful consideration to the processing implications, routine blend uniformity analysis should not be a required in-process test on validated and well-controlled processes. The technical issues concerning blend uniformity analysis should be addressed through PQRI before further refining this draft guidance.

We trust that these comments will be considered in further development of the draft guidance.

Sincerely,

A handwritten signature in dark ink, appearing to read "Dennis M. Erb". The signature is fluid and cursive, with a prominent initial "D".

Dennis M. Erb, Ph.D.

Senior Director, Regulatory Affairs

Q/ligi/guidance/blenduniform

**FedEx** USA AirbillFedEx  
Tracking  
Number

810495663575

Form  
ID No.

0210

SPH32

Recipient's Copy

**1 From**  
Date 10/26/99

Sender's Name Dennis M. Erb, Ph.D. Phone 610 ) 397-7053

Company MERCK SHARP & DOHME

Address 5 SENTRY PKWY WEST BLA-20

Dept./Floor/Suite/Room

City BLUE BELL State PA ZIP 19422

**2 Your Internal Billing Reference Information**

**3 To**  
Recipient's Name Dockets Mgmt. Branch Phone ( )

Company Food and Drug Administration

Address 5630 Fishers Lane Room 1061

(To "HOLD" at FedEx location, print FedEx address here)

Dept./Floor/Suite/Room

City Rockville State MD ZIP 20852

**For HOLD at FedEx Location check here**


☐ **Hold Weekday**  
(Not available with  
FedEx First Overnight)

☐ **Hold Saturday**  
(Not available at all locations  
and FedEx 2Day only)

**For WEEKEND Delivery check here**

☐ **Saturday Delivery**  
(Available for FedEx Priority  
Overnight and FedEx 2Day only)

☐ **NEW Sunday Delivery**  
(Available for FedEx  
Priority Overnight only)



8 1 0 4 9 5 6 6 3 5 7 5

**4a Express Package Service Packages under 150 lbs.** Delivery commitment may be later in some areas.

☒ **FedEx Priority Overnight** (Next business morning)  
☐ **FedEx Standard Overnight** (Next business afternoon)  
☐ **FedEx First Overnight** (Earliest next business morning delivery to select locations) (Higher rates apply)  
☐ **FedEx 2Day** (Second business day)  
☐ **FedEx Express Saver** (Third business day)  
 FedEx Letter Rate not available. Minimum charge: One pound rate.

**4b Express Freight Service Packages over 150 lbs.** Delivery commitment may be later in some areas.

☐ **FedEx Overnight Freight** (Next business day)  
☐ **FedEx 2Day Freight** (Second business day)  
☐ **FedEx Express Saver Freight** (Up to 3 business days)  
 (Call for delivery schedule. See back for detailed descriptions of freight services.)

**5 Packaging** ☒ **FedEx Letter** ☐ **FedEx Pak** ☐ **FedEx Box** ☐ **FedEx Tube** ☐ **Other Pkg.**  
 Declared value limit \$500 (One box must be checked)

**6 Special Handling**  
 Does this shipment contain dangerous goods? ☐ No ☒ Yes (Shipper's Declaration not required) ☐ Yes (Shipper's Declaration required)  
☐ **Dry Ice** Dry Ice 9/1N 1845 x kg. ☐ **Cargo Aircraft Only**  
 \*Dangerous Goods cannot be shipped in FedEx packaging

**7 Payment**  
 Bill to: ☒ **Sender** (Account No. in Service 1 will be billed) ☐ **Recipient** (Enter FedEx Account No. or Credit Card No. below) ☐ **Third Party** ☐ **Credit Card** ☐ **Cash/Check**  
☐ **Obtain Recipient FedEx Account No.**



Total Packages Total Weight Total Declared Value\* Total Charges  
 \$ .00 \$

\*When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information. Credit Card Auth.

**8 Release Signature**

Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

**Questions?**

Call 1-800-Go-FedEx® (800)463-3339

321

WCSL 1298  
 Rev. Date 7/98  
 Part #153023ps  
 ©1994 FedEx  
 PRINTED IN U.S.A.

0085547061